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Policy Forum
B
rucellosis is probably the 
commonest anthropozoonotic 
infection worldwide [1–3], 
but remains in various aspects an 
enigma in the 21st century [4]. 
Brucella melitensis remains the major 
cause of human disease worldwide, 
followed by B. abortus and B. suis,
while rare but persisting cases of B.
canis human infection and disease by 
novel Brucella pathogens of marine 
mammals have also emerged. The 
disease is re-emerging as a signiﬁcant 
cause of travel-related disease [5]
and represents an index of poor 
socioeconomic status (Figure 1). Its 
treatment is largely based even today 
on the principles applied half a century 
ago by pioneer researchers [6] and few 
modiﬁcations have been made in the 
following years, despite the emergence 
of new antibiotic classes and different 
therapeutic approaches [7].
The World Health Organization 
(WHO) issued recommendations for 
the treatment of human brucellosis 
in 1986 [8], suggesting the use of 
doxycycline, 100 mg twice daily for 
six weeks combined with either 
rifampicin, 600–900 mg daily for six 
weeks, or streptomycin, 1 g daily for 
2–3 weeks. During the following years, 
a number of clinical studies assessed 
the efﬁcacy of different regimens. 
Furthermore, reports from various 
regions of the world revealed that the 
WHO-recommended regimens have 
not been universally applied in clinical 
practice. More importantly, these 
regimens still allow for a small, albeit 
signiﬁcant percentage of therapeutic 
failures, most commonly in the form 
of relapses, ranging from 5% to 15% 
of uncomplicated cases. Although 
these relapses are usually mild and can 
be treated successfully with the same 
regimens, they represent a signiﬁcant 
morbidity factor. Risk factors for 
relapse have been assessed [9,10], but 
it remains unclear what is the best 
regimen to be used in their presence.
Another controversial subject in 
brucellosis treatment has been the 
duration of therapy: If the treatment 
is prolonged, the risk of relapse 
progressively decreases. Obviously, 
deﬁning an acceptable relapse rate 
based on the duration of the schedule 
used is somewhat arbitrary.
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Summary Points
u Brucellosis remains the commonest 
anthropozoonosis worldwide, and its 
treatment remains complex, requiring 
protracted administration of more 
than one antibiotic.
u In November 2006, a consensus 
meeting aimed at reaching a common 
specialist statement on the treatment 
of brucellosis was held in Ioannina, 
Greece under the auspices of the 
International Society of Chemotherapy 
and the Institute of Continuing Medical 
Education of Ioannina. 
u The author panel suggests that the 
optimal treatment of uncomplicated 
brucellosis should be based on a 
six-week regimen of doxycycline 
combined either with streptomycin for 
2–3 weeks, or rifampicin for six weeks. 
Gentamicin may be considered an 
acceptable alternative to streptomycin, 
while all other regimens/combinations 
should be considered second-line.
u The development of a common 
global therapeutic language for 
human brucellosis, and future, 
properly conducted clinical trials 
would deﬁnitely solve controversies 
regarding the disease.PLoS Medicine  |  www.plosmedicine.org 1873 December 2007  |  Volume 4  |  Issue 12  |  e317
In an era of rapid emergence of 
antimicrobial resistance, controversies 
regarding the prolonged use of 
antibiotics with established activity 
against Brucella pose special problems. 
In some endemic regions, especially 
in the developing world, brucellosis 
and tuberculosis coexist in the same 
communities. So for example, for 
those medications active against 
tuberculosis that are also used for 
the treatment of brucellosis, such 
as rifampicin, there is an increased 
potential in the community for 
emergence of mycobacterial resistance 
to these antimicrobials because of 
their use against brucellosis.. The 
public health signiﬁcance of such 
resistance may be far larger than the 
cumulative brucellosis morbidity [11]. 
Finally, it should be kept in mind that 
the majority of human and animal 
brucellosis cases occur in resource-
deprived countries of the developing 
world. Therefore, the cost of the new, 
sophisticated antimicrobials should be 
taken into account when designing an 
effective therapy for a large number of 
patients.
Development of the “Ioannina 
Recommendations”
In November 2006, the 1st 
International Meeting on the 
Treatment of Human Brucellosis was 
held in Ioannina, Greece, co-organized 
by the Institute of Continuing 
Medical Education of Ioannina 
and the International Society of 
Chemotherapy, as part of the latter’s 
Disease Management Series. The 
aims of the meeting were to: review 
the current situation of the disease 
worldwide; summarize the existing 
knowledge regarding the pathogenesis 
of risk factors for, and natural history 
of, brucellosis; review recent basic 
science and clinical developments in 
the ﬁeld of diagnosis and treatment 
of brucellosis; and set the background 
for the production of a statement on 
the current optimal diagnosis and 
treatment options of human disease.
Selected experts were assigned to 
review all existing literature data, 
each on a speciﬁc aspect of human 
brucellosis treatment, and present 
them by analyzing the strength of 
evidence regarding each particular 
treatment option; a ﬁnal session was 
held in order to set up the framework 
for the development of a common 
statement offering clinical perspectives 
for the 21st century. The statement was 
developed as a draft and re-circulated 
among the authors until a ﬁnal form 
approved by all authors was reached. 
In developing the present therapeutic 
recommendations, guidelines of the 
Infectious Disease Society of America 
have been used (Table 1). The current 
recommendations are summarized in 
Table 2.
A second position paper on the 
optimal diagnosis of the disease is 
currently under preparation.
Efﬁcacy of the WHO-
Recommended Regimens
A meta-analysis performed in 1995 
[12] evaluated the efﬁcacy of the 
two WHO-recommended regimens 
and concluded that the efﬁcacy 
of the doxycycline-streptomycin 
(DOX-STR) regimen was superior 
to that of the doxycycline-rifampicin 
(DOX-RIF) regimen, as already 
suggested by previous studies [13–15]. 
Even if subsequent randomized 
therapeutic trials were to be added 
to a future meta-analysis, the slight 
superiority of DOX-STR is obvious. 
The superior efﬁcacy of the DOX-
STR regimen was further supported 
by pharmacokinetic data (lower 
doxycycline serum levels induced 
by co-administration of rifampicin) 
[16,17] and resistance-related data: 
prolonged administration of rifampicin 
for brucellosis may increase the 
resistance of Mycobacterium tuberculosis 
to this compound in endemic areas. 
Moreover, experimental data suggested 
that the development of mycobacterial 
resistance to rifampicin may lead to 
doi:10.1371/journal.pmed.0040317.g001
Figure 1. The Global Incidence of Human Brucellosis
Reproduced from: Gutierrez Ruiz C, Miranda JJ, Pappas G (2006) A 26-year-old man with sternoclavicular arthritis. PLoS Med 3(8): e293. doi:10.1371/
journal.pmed.0030293 Derived from: Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV (2006) The new global map of human brucellosis. 
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development of resistance to other 
antimicrobials as well [18]. 
On the other hand, two recent 
studies have shown that the DOX-
RIF regimen is preferred by both 
clinicians [19] and patients [20], 
even when they are aware of the 
relative superiority of the alternative 
regimen. The fact that DOX-RIF is an 
all-oral regimen may allow for better 
implementation in clinical practice in 
areas with less well-developed health 
infrastructure, because it eliminates 
the need for parenteral administration 
of streptomycin as part of the 
DOX-STR regimen. Furthermore, 
streptomycin shortage in numerous 
areas of the world may hamper the 
implementation of the DOX-STR 
regimen. Although evidence-based 
medicine would suggest that the 
DOX-STR regimen should always be 
offered, particularly in patients with 
complicated or serious forms of the 
disease, convenience, which can be 
translated into better adherence and 
overall success rates, forces the authors 
to suggest that DOX-RIF could be 
considered as an acceptable ﬁrst-line 
regimen as well. 
Regarding potential side-effects of 
these combinations, the authors suggest 
that the ototoxicity and nephrotoxicity 
of the aminoglycoside-containing 
regimens should be more thoroughly 
investigated in future randomized 
trials. The authors stress the need for 
inclusion of a tetracycline antibiotic 
in any therapeutic regimen for adult 
brucellosis. Various trials have been 
performed with combinations omitting 
such a compound, often reporting 
adequate results; yet understanding 
the pathophysiology of the disease 
renders the inclusion of tetracyclines 
imperative.
Monotherapy
Monotherapy for brucellosis has 
generally been considered inadequate 
due to unacceptably high relapse rates. 
In older studies the use of tetracyclines 
as monotherapy was associated with 
varying relapse rates, ranging from 
2% to 39% [21–26]. Nevertheless, 
these studies have major drawbacks: 
they were not randomized, they used 
doubtful diagnostic criteria, and the 
duration of treatment and adequacy of 
follow-up were widely varying. However, 
these criticisms do not apply to the 
excellent randomized comparative 
therapeutic trial performed by Montejo 
and colleagues [24]. This study showed 
that doxycycline monotherapy (100 mg 
twice daily for six weeks) is associated 
with relapse rates similar to the WHO-
recommended regimen of DOX-RIF. 
The use of either trimethoprim-
sulfamethoxazole (TMP-SMX) [24–31] 
or rifampicin [26,32] as monotherapy 
has also been reported in the past in 
adult brucellosis patients, with similarly 
varying results and similar reservations 
concerning the adequacy of the study 
design. A well-designed trial with TMP-
SMX used for 45 days demonstrated a 
relapse rate of 46% [33].
Newer antibiotics such as 
ciproﬂoxacin and ceftriaxone have 
been tested as monotherapy in 
brucellosis in the past years, with 
disappointing results [34,35].
In the absence of deﬁnite data 
from randomized trials, the authors 
concluded, although not unanimously, 
that the available studies cannot 
convincingly support the use of 
monotherapy in human brucellosis. 
The authors however strongly 
recommend carefully designed 
prospective randomized clinical trials 
assessing the efﬁcacy and safety of 
tetracycline monotherapy in patients 
with low relapse risk according to 
published data on relapse risk factors 
[9,10]. However, future single-regimen 
trials with other antibiotic classes are 
not justiﬁed.
The Doxycycline-Gentamicin 
Regimen
Non-comparative studies on the efﬁcacy 
of the combination of doxycycline and 
gentamicin (DOX-GENT) in brucellosis 
usually used shorter schedules of 
aminoglycosides than those of the 
standard regimens (i.e., 5–7 days for 
gentamicin) [12,36–38] with failure/
relapse rates ranging from 10% to 20% 
(the latter when doxycycline treatment 
duration was also shortened), which 
exceeded failure rates during the 
WHO-recommended treatment by 
about 5%. In the only randomized trial 
available of doxycycline administered 
for six weeks in combination with 
gentamicin for seven days, relapse 
rates were at least comparable to those 
reported for the WHO-recommended 
regimens [36].
The authors consider the DOX-
GENT combination to be an adequate 
regimen for the treatment of human 
brucellosis that offers advantages 
over DOX-STR, given the wider 
availability of gentamicin and the 
sparing of streptomycin, a valuable 
anti-tuberculosis agent. However, the 
duration of gentamicin treatment 
should be further evaluated in future 
randomized control trials, as the 
Table 1. Infectious Diseases Society of America   United States Public Health Service Grading System for Ranking Recommendations in 
Clinical Guidelines
Category, Grade Deﬁnition
Strength of recommendation
A Good evidence to support a recommendation for use; should always be offered
B Moderate evidence to support a recommendation for use; should generally be offered
C Poor evidence to support a recommendation; optional
D Moderate evidence to support a recommendation against use; should generally not be offered
E Good evidence to support a recommendation against use; should never be offered
Quality of evidence
I Evidence from 1 properly randomized, controlled trial
II Evidence from 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably 
from >1 center); from multiple time-series; or from dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees
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authors were divided on whether 
gentamicin administration should be 
prolonged.
The aminoglycoside-containing 
combinations raise concerns about the 
applicability of a parenteral regimen in 
resource-deprived countries, because 
of the need for an adequate health 
infrastructure (for example walk-
in clinics, staffed with experienced 
personnel, to deliver intramuscular 
injections daily) to eliminate the 
necessity of hospitalization, which 
would increase the overall treatment 
cost.
Although there are no brucellosis-
speciﬁc data, the existing data 
support the feasibility of once-
daily aminoglycoside dosing [39]. 
Interventions with gentamicin-
encapsulated microspheres have shown 
promise in animal models and may 
prove useful alternative options in the 
future [40].
Fluoroquinolone-Containing
Regimens
Two recent reviews focused on 
ﬂuoroquinolone-containing regimens 
for the treatment of brucellosis 
[41,42]. Both reviews, although 
using different approaches, conclude 
that combinations including 
ﬂuoroquinolones can be acceptable 
alternatives, but do not recommend 
them as ﬁrst-line options for human 
brucellosis treatment. According to the 
ﬁrst review, the few proper randomized 
trials existing on the subject do not 
indicate the superiority or even 
non-inferiority of ﬂuoroquinolone-
containing regimens. The second 
review reports a cumulative response 
rate of above 85%, which is an adequate 
response; however, the currently 
higher cost of ﬂuoroquinolone-
containing regimens and the risk 
of enhancing the development of 
overall ﬂuoroquinolone resistance 
in the community argue against wide 
use of ﬂuoroquinolones for human 
brucellosis. The authors feel that in 
the future, if older ﬂuoroquinolones 
become less expensive, further properly 
designed randomized trials may 
explore their potential in combined 
brucellosis treatment. There are 
no data, apart from sporadic case 
reports, on the efﬁcacy of the newer 
ﬂuoroquinolones in brucellosis, but 
in view of their unique efﬁcacy against 
respiratory pathogens the authors 
do not recommend their routine 
use in brucellosis. Therefore, these 
antibiotics should be administered only 
in the context of properly designed 
prospective clinical trials.
TMP-SMX-Containing Regimens
TMP-SMX has been a popular 
choice, and was included in various 
combination regimens around the 
world, due to its signiﬁcantly lower cost 
(compared to other antimicrobials 
included in treatment regimens for 
brucellosis), which rendered it the most 
cost-effective drug against brucellosis 
in certain developing world counties. 
Data on its interaction with rifampicin 
suggest a potential beneﬁcial increase 
in the latter’s serum levels [43], but a 
synergistic effect has not been proven 
[44,45]. TMP-SMX combination with 
rifampicin has proven successful in 
many reports of pediatric brucellosis. 
In adults, a recent randomized study 
suggested an adequate (but not 
superior) response rate comparable 
to the WHO-recommended regimens, 
although the treatment duration 
was extended [46]. Past studies have 
produced contradicting results, with 
relapse rates ranging from 0% to 
30% (TMP-SMX combinations with 
tetracycline) [25,47]. 
TMP-SMX has been extensively 
used in triple combinations in some 
countries. The overall reported 
response rate was above 90% for 
the various TMP-SMX-containing 
combinations, although the absence 
of doxycycline from the regimen 
was related to an unacceptably high 
percentage of treatment failures 
(M. Bosilkovski, unpublished data). 
These data were derived from clinical 
studies which included patients with 
severely complicated disease; therefore 
extrapolation of these conclusions to 
patients with uncomplicated brucellosis 
is not easy. At present, the routine use 
of a triple regimen containing TMP-
SMX cannot be advocated. However, 
the authors suggest that, depending on 
the regional overall failure rates of the 
WHO-recommended regimens, TMP-
SMX may be used as an additional third 
(and only third) antibiotic.
One important issue regarding 
the use of TMP-SMX in brucellosis 
Table 2. The recommendations of Ioannina on the Optimal Treatment of Brucellosis Without Serious Complications in Adults
Treatment Regimen Dose Recommendation
Validation
Comments
DOX-STR DOX: 100 mg twice daily orally for 6 weeks; STR: 15 mg/kg 
daily intramuscularly for 2–3 weeks
AI Considered the “gold standard.”
DOX-RIF DOX: as above; RIF: 600–900 mg daily for 6 weeks, one 
morning dose
AI Convenience of the regimen overcomes 
slight drawbacks concerning the 
pharmacokinetics of the combination 
and the overall outcome.
DOX-GENT DOX: as above; GENT: 5 mg/kg daily parenterally in 1 dose 
for 7 days
BI May be considered the preferred 
alternative regimen. Duration of GENT 
administration may need modiﬁcation 
for optimal result (different studies 
suggest that it may be shortened to 5 
days or extended to 14 days).
TMP-SMX-containing regimens TMP-SMX: 800 + 160 mg twice daily for 6 weeks CII Recommendation referring to three-
drug regimens containing DOX. 
Quinolone-containing combination 
regimens
Oﬂoxacin: 400 mg twice daily for 6 weeks; ciproﬂoxacin: 500 
mg twice daily for 6 weeks
CII Oﬂoxacin or ciproﬂoxacin may be used 
alternatively as second or third agents in 
combination regimens containing DOX.
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treatment is the development of 
resistance in B. melitensis. Previous 
studies have suggested that TMP-SMX 
use has been associated with increasing 
B. melitensis resistance rates, sometimes 
reaching 62% [48,49]. Resistance 
rates may vary over time, reﬂecting the 
antibiotics’ overall use for brucellosis 
[50]. If a DOX/TMP-SMX combination 
is to be considered for a future clinical 
trial, the problem of resistance to TMP-
SMX should be seriously taken into 
account. (The well-known dissociation 
between in vitro activity and in vivo 
activity—i.e., therapeutic failure in 
vivo—in brucellosis refers only to drugs 
with in vitro activity and not in vivo, 
but not vice versa. This means that if 
in vitro activity is absent, for example 
as with most beta-lactams, clinical 
failure is guaranteed.) In future studies, 
isolated strains should be carefully 
studied for resistance to TMP-SMX and 
the other agents active against Brucella, 
and the relation of overall antibiotic 
use to the development of resistance 
should be analyzed in every region.
Other Tetracyclines and Related 
Compounds
A number of Italian studies have 
investigated the use of minocycline 
instead of doxycycline in the treatment 
of brucellosis. Early studies from 
the 1980s used minocycline either 
as monotherapy or in combination 
with intravenous rifampicin for 
short periods (2–4 weeks); both 
antimicrobials were delivered initially 
intravenously and subsequently orally. 
All of the above studies reported very 
low relapse rates, and were summarized 
in a recent article [51]. However, 
these data should be interpreted 
cautiously because the studies were 
retrospective and not comparative. The 
potential superiority of minocycline 
over doxycycline could be attributed 
to its increased bioavailability and 
the increased area under the curve 
of free minocycline compared to free 
doxycycline, as well as minocycline’s 
greater lipophilicity, which allows 
for better tissue penetration [52]. 
The authors stress that, given wide 
anecdotal reports of lower adherence 
to minocycline treatment (compared 
to doxycycline), a combination 
including minocycline would have 
to prove far superior compared 
to doxycycline to merit further 
consideration.
Regarding oxytetracycline, at 
present it might be considered as a 
less convenient, in terms of multiple 
daily doses, but adequate alternative to 
doxycycline.
Tigecycline is the ﬁrst glycylcycline 
antibiotic, a new member of the 
tetracycline family with chemical 
structure similar to that of minocycline. 
The drug has the ability to overcome 
the two major resistance mechanisms of 
tetracycline—drug-speciﬁc efﬂux pump 
acquisition and ribosomal protection—
and is active against many gram-positive 
and gram-negative organisms [53].The
authors believe that the potential role 
of this new compound in the treatment 
of brucellosis may be hampered by 
problems such as the cost and the need 
for parenteral administration; a future 
clinical trial using this compound 
would need to show substantial 
superiority regarding efﬁcacy and 
treatment duration in order to 
overcome these reservations. Future 
studies should also explore a possible 
role of tigecycline in the therapy of 
serious clinical forms of the disease 
requiring intravenous antibiotics.
Antibiotics Not Suitable for 
Brucellosis Treatment
Numerous other antibiotic classes have 
been clinically tested in the treatment 
of brucellosis. Azithromycin has been 
shown to be inadequate in a small 
but well-randomized trial [54]. Data 
from literature from Russia suggest 
a potential role for meropenem 
[55], yet the cost and importance of 
this agent for the treatment of more 
serious infections lead the authors 
to advocate against further clinical 
trials with this agent. However, its use 
might be considered in an individual 
hospitalized case as an alternative or as 
salvage therapy.
Special Situations
Treatment of brucellar spondylitis 
varies widely; one recent attempt at 
a meta-analysis of the existing data 
concluded that what matters for the 
outcome is the duration of treatment, 
and not the speciﬁc (recommended) 
regimen used [56]. However, many of 
the authors believe that some principles 
do apply in the treatment of brucellar 
spondylodiscitis: aminoglycoside-
containing regimens may be superior 
to rifampicin-containing ones [57]; 
magnetic resonance imaging (MRI) of 
the spine should always be performed 
when there is clinical suspicion of 
spinal involvement irrespective of the 
rachideal level potentially affected; and 
the spine (especially if there is cervical 
involvement) should be immobilized 
in order to avoid devastating 
neurological complications. Although 
the previously mentioned meta-analysis 
did not conclude that a streptomycin-
containing regimen may be superior, 
the authors suggest that the outcome 
of spondylitis may potentially be 
improved when such a regimen is 
used. According to certain authors 
this approach may be successful (in 
patients who have spondylitis only and 
not associated paravertebral or epidural 
abscess) even if duration of treatment 
is limited to the six weeks’ therapeutic 
course used in uncomplicated 
brucellosis [58]. At present though, 
the available data support a longer 
duration of treatment of not less 
than three months [56,59]. Another 
important subject for future properly 
designed clinical trials would be the 
utility of MRI in the follow-up of these 
patients, since conﬂicting data exist 
on the subject, i.e., should treatment 
be continued until resolution of spinal 
MRI ﬁndings or not.
Neurobrucellosis is a term 
encompassing a wide spectrum 
of central nervous system clinical 
manifestations. Although central 
nervous system involvement is probably 
more common than originally 
considered, the paucity of therapeutic 
data preclude any recommendations to 
be offered for the time being.
Childhood brucellosis will be 
discussed in a separate statement 
currently being developed.
There are no randomized trials for 
brucellosis in pregnancy. The most 
extended series support the use of 
TMP-SMX alone or in combination 
with rifampicin [60]. The potential 
for adverse effects on the fetus from 
antimicrobials makes brucellosis 
in pregnancy a key situation where 
monotherapy trials are needed. For 
example, patients without risk factors 
for relapse or those without focal 
disease may be treated with rifampicin 
monotherapy (arguably the safer of 
all available antibiotics for brucellosis 
in pregnancy) until delivery. The 
advantage of minimizing the risks for 
fetal health is counterbalanced by the 
disadvantage of higher relapse rates; PLoS Medicine  |  www.plosmedicine.org 1877 December 2007  |  Volume 4  |  Issue 12  |  e317
however, in case of postpartum relapse, 
the patient can be treated with a 
standard regimen.
Brucellar endocarditis is a notorious 
complication with high mortality 
that has been reported fewer than 
200 times in the literature; therefore 
no randomized data are available. 
Although a report has suggested 
that certain factors may allow for 
conservative treatment [61], the 
selection of antimicrobials remains 
empirical; in the majority of reported 
cases surgical intervention was 
necessary. The authors suggest that 
through a large, international database 
of brucellosis cases more endocarditis 
cases could be recorded, and the 
risk factors, pathophysiology, natural 
history, and clinical characteristics 
of this complication could be better 
characterized. This information would 
enable the design of an effective 
therapeutic approach.
Developing a Common Language
One of the major obstacles in the 
clinical research on brucellosis is 
the absence of properly designed 
and randomized therapeutic trials. 
Standards applying to typical 
bacterial infections cannot be easily 
implemented in brucellosis research; 
the concept of microbiological cure 
is vague in brucellosis. Moreover, the 
concept of relapse is in itself vague as 
well: is relapse a clinical failure? And 
if so, what is the required period of 
follow-up after treatment completion? 
The pathogen’s virulence may also vary 
in different regions of the world: this 
variation is not only because of different 
Brucella strains (B. melitensis versus B. 
abortus, etc.), but also to different B. 
melitensis biovars that are endemic in 
each country. Important issues that 
should be addressed in the future 
include the optimization of treatment 
adherence, the monitoring for potential 
adverse effects, the importance of 
expert consultation in complicated 
disease, and the importance of a good 
relationship between patients and 
physicians, which is essential for a better
prognosis, especially in cases of chronic 
brucellosis. 
Regarding the nature of chronic 
disease: All attempts to categorize the 
disease have been hampered by the 
lack of agreement on terminology and 
the arbitrary nature of the designations. 
Nevertheless, many published works 
divide patients into acute versus 
chronic disease, often based on clinical 
complaints alone, or on some arbitrary 
number of days of symptoms. Although 
this classiﬁcation does not usually affect 
the regimens used in various antibiotic 
treatment studies, the development of a 
common terminology is of paramount 
importance in order to better design 
effectively large, international, 
multicenter clinical studies.  
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